Surgical and interventional therapies for pulmonary arterial hypertension

被引:14
|
作者
Olsson, JK
Zamanian, RT
Feinstein, JA
Doyle, RL
机构
[1] Stanford Univ, Sch Med, Div Pulm & Crit Care Med, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Div Pediat Cardiol, Stanford, CA USA
[3] Stanford Univ, Sch Med, Vera M Wall Ctr Pulm Vasc Dis, Stanford, CA USA
关键词
pulmonary arterial hypertension; congenital heart disease; pulmonary thromboendarterectomy; lung and heart-lung transplantation; atrial septostomy;
D O I
10.1055/s-2005-916157
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Surgical and interventional therapies for pulmonary arterial hypertension (PAH) in appropriately selected patients have the potential to dramatically improve or, in some cases, cure PAH. These include atrial septostomy, a palliative procedure or bridge to transplantation in patients with refractory right heart failure, pulmonary thromboendarterectomy for pulmonary hypertension associated with chronic thromboembolic disease, and closure of congenital systemic-pulmonary shunts in patients with PAH but without significant pulmonary vascular disease. Lung transplantation should be considered for patients with all forms of PAH who demonstrate advanced or progressive disease.
引用
收藏
页码:417 / 428
页数:12
相关论文
共 50 条
  • [21] Pulmonary arterial hypertension: updates and perspective with newer therapies
    Prasad, Jyotika D.
    Williams, Trevor J.
    Whitford, Helen M.
    INTERNAL MEDICINE JOURNAL, 2024, 54 (12) : 1944 - 1951
  • [22] Update on targeted therapies in pediatric pulmonary arterial hypertension
    Bonnet, D.
    Levy, M.
    Bajolle, F.
    REANIMATION, 2013, 22 (02): : S359 - S364
  • [23] Targeted Oral Therapies in the Treatment of Pulmonary Arterial Hypertension
    Zeenat Safdar
    Clinical Drug Investigation, 2010, 30 : 811 - 826
  • [24] Targeted Therapies in Patients with Pulmonary Arterial Hypertension Due to Congenital Heart Disease
    Mares, Adriana
    Mukherjee, Debabrata
    Lange, Richard A. A.
    Nickel, Nils P. P.
    CURRENT VASCULAR PHARMACOLOGY, 2022, 20 (04) : 341 - 360
  • [25] Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies
    Spaczynska, Monika
    Rocha, Susana F.
    Oliver, Eduardo
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (04) : 598 - 612
  • [26] Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension
    Santos, Renata Trabach
    Onofre, Maria Eduarda de Sa Freire
    Caldeira, Dayene de Assis Fernandes
    Klein, Adriane Bello
    Rocco, Patricia Rieken Macedo
    Cruz, Fernanda Ferreira
    Silva, Pedro Leme
    CURRENT VASCULAR PHARMACOLOGY, 2024, 22 (03) : 155 - 170
  • [27] Pulmonary arterial hypertension: pharmacologic therapies and potential pulmonary artery denervation treatment
    Zhang, Yao-Jun
    Li, Ming-Hui
    Chen, Shao-Liang
    EUROINTERVENTION, 2013, 9 : R149 - R154
  • [28] Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis
    Yasuhara, Jun
    Watanabe, Kae
    Watanabe, Atsuyuki
    Shirasu, Takuro
    Matsuzaki, Yuichi
    Watanabe, Hirofumi
    Takagi, Hisato
    Sumitomo, Naokata
    Kuno, Toshiki
    CARDIOLOGY IN THE YOUNG, 2023, 33 (11) : 2297 - 2311
  • [29] Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension
    Idrees, Majdy M.
    Swiston, John
    Nizami, Imran
    Al Dalaan, Abdullah
    Levy, Robert D.
    ANNALS OF THORACIC MEDICINE, 2014, 9 (05) : 79 - 91
  • [30] Epidemiology of Pulmonary Arterial Hypertension
    Xin Jiang
    Zhi-Cheng Jing
    Current Hypertension Reports, 2013, 15 : 638 - 649